Progress on baculovirus-derived influenza vaccines

Area of Science:

• Biotechnology
• Vaccinology
• Virology

Background:

• Annual influenza vaccine composition changes necessitate rapid production methods.
• Baculovirus insect cell technology offers a platform for producing influenza vaccine antigens.
• Current influenza vaccines can be improved with additive components like neuraminidase.

Purpose of the Study:

• To review the development of influenza vaccine candidates using baculovirus expression technology.
• To discuss various influenza vaccine targets including hemagglutinin, neuraminidase, M2, nucleoprotein, and virus-like particles (VLPs).
• To analyze the progress, advantages, and disadvantages of each vaccine candidate.

Main Methods:

• Review of scientific literature on baculovirus-produced influenza vaccine candidates.
• Analysis of recombinant protein expression, immunogenicity, and efficacy data.
• Comparison of different vaccine targets and production strategies.

Main Results:

• Recombinant hemagglutinin produced via baculovirus is safe, immunogenic, and effective against influenza.
• Recombinant neuraminidase shows potential as an additive to enhance current influenza vaccines.
• Virus-like particle (VLP) vaccine candidates are in clinical development, alongside other universal vaccine targets.

Conclusions:

• Baculovirus insect cell technology is a viable and rapid platform for producing diverse influenza vaccine candidates.
• Recombinant hemagglutinin and neuraminidase show promise for improved influenza prevention and vaccine formulation.
• Further clinical development is ongoing for universal influenza vaccine candidates and VLPs.